All‐cause mortality · adults undergoing cardiac surgery with cardiopulmonary bypass
It is very uncertain whether high changes all‐cause mortality compared with low blood pressure target (very low certainty).
1 finding from 1 review
All‐cause mortality – deaths · adults with or without existing CVD
High showed no clear difference in all‐cause mortality – deaths compared with low long‐chain omega‐3 fats (high certainty).
1 finding from 1 review
All‐cause mortality – deaths · adults with or without existing CVD
High showed no clear difference in all‐cause mortality – deaths compared with low alpha‐linolenic acid omega‐3 fats (moderate certainty).
1 finding from 1 review
All‐cause mortality: range 1 mo to 1 y · adults admitted to the ICU
It is very uncertain whether higher changes all‐cause mortality: range 1 mo to 1 y compared with lower FiO2 or targets of arterial oxygenation (very low certainty).
1 finding from 1 review
All‐cause mortality · Adults without diabetes or CVD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (low certainty).
1 finding from 1 review
All‐cause mortality Study duration range 12‐96 months Omega‐6 dose range 1.5%‐24.5% E · adults with or without existing CVD
Higher showed no clear difference in all‐cause mortality Study duration range 12‐96 months Omega‐6 dose… compared with lower omega‐6: primary outcomes (low certainty).
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
All‐cause mortality · people hospitalised with COVID‐19
Higher‐dose anticoagulants showed no clear difference in all‐cause mortality compared with lower‐dose anticoagulants (high certainty).
1 finding from 1 review
Mortality before hospital discharge · preterm infants with or at risk for apnea of prematurity
High‐dose showed no clear difference in all‐cause mortality prior to hospital discharge compared with standard‐dose strategies (low certainty).
3 findings from 1 review
RR 0.86 [0.53, 1.38]
5 studies · 723 participants
Low
RR 0.75 [0.4, 1.4]
3 studies · 333 participants
Very low
RR 0.75 [0.25, 2.3]
1 study · 238 participants
Very low
Mortality before hospital discharge · preterm infants at risk for apnea
It is very uncertain whether high‐dose changes all‐cause mortality prior to hospital discharge compared with standard‐dose strategies (very low certainty).
1 finding from 1 review
All‐cause mortality · people with or without existing CVD, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in all‐cause mortality compared with lower PUFA (moderate certainty).
1 finding from 1 review
All‐cause mortality · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
All‐cause mortality · adults with severe acute pancreatitis
High‐volume continuous veno‐venous hemofiltration (CVVH) showed no clear difference in all‐cause mortality compared with standard CVVH (low certainty).
1 finding from 1 review
All‐cause mortality during hospital stay · people with critical limb ischaemia
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · people suffering from high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality · people suffering from high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found